Global Tuberculosis Report -- 2012.pdf

More documents

Recommendations

Info

WHO AFRICAN REGIONPopulation 2011 857 millionWHO MEMBER STATES 46Estimates of TB burden a 2011 NUMBER (thousands)RATE (per 100 000 population)Mortality (excludes HIV+TB) 220 (180–270) 26 (21–31)Prevalence (includes HIV+TB) 2 500 (2 100–3 000) 293 (243–347)Incidence (includes HIV+TB) 2 300 (2 100–2 400) 262 (242–283)Incidence (HIV+TB) 870 (800–950) 102 (93–111)Case detection, all forms (%) 61 (56–66)TB case notifications 2011NEW CASES (%) RETREATMENT CASES (%)Smear-positive 605 929 (46) Relapse 52 283 (41)Smear-negative 357 811 (27) Treatment after failure 9 271 (7.3)Smear-unknown/not done 109 258 (8.3) Treatment after default 13 498 (11)Extrapulmonary 240 843 (18) Other 51 853 (41)Other 1 069 (
WHO REGION OF THE AMERICASPopulation 2011 943 millionWHO MEMBER STATES 35OTHER COUNTRIES AND TERRITORIES 11Estimates of TB burden a 2011 NUMBER (thousands)RATE (per 100 000 population)Mortality (excludes HIV+TB) 21 (18–24) 2.2 (1.9–2.5)Prevalence (includes HIV+TB) 330 (250–420) 35 (26–44)Incidence (includes HIV+TB) 260 (240–280) 28 (26–29)Incidence (HIV+TB) 37 (34–40) 3.9 (3.6–4.2)Case detection, all forms (%) 84 (79–89)TB case notifications 2011NEW CASES (%) RETREATMENT CASES (%)Smear-positive 121 130 (59) Relapse 10 004 (46)Smear-negative 36 371 (18) Treatment after failure 1 066 (4.9)Smear-unknown/not done 14 254 (6.9) Treatment after default 6 506 (30)Extrapulmonary 33 757 (16) Other 4 041 (19)Other 1 315 (
Page 2 and 3:
GLOBALTUBERCULOSISREPORT2012
Page 4 and 5:
ContentsAbbreviationsivAcknowledgem
Page 6 and 7:
AcknowledgementsThis report on glob
Page 8 and 9:
WHO Western Pacific RegionShalala A
Page 10 and 11:
Executive SummaryThe World Health O
Page 12 and 13:
CHAPTER 1IntroductionBOX 1.1Basic f
Page 14 and 15:
TABLE 1.1 Targets for the scale-up
Page 16 and 17:
TABLE 1.2 Reporting of data in the
Page 18 and 19:
BOX 2.1Uncertainty in estimates of
Page 20 and 21:
TABLE 2.2 Estimated burden of disea
Page 22 and 23:
FIGURE 2.5 Estimated TB incidence r
Page 24 and 25:
FIGURE B2.2.1Reporting of notificat
Page 26 and 27:
FIGURE 2.8Estimated TB incidence ra
Page 28 and 29:
FIGURE 2.11 Countries (in blue) for
Page 30 and 31:
FIGURE 2.12 Trends in estimated TB
Page 32 and 33:
● producing and widely disseminat
Page 34 and 35:
FIGURE 2.16 Progress in global cove
Page 36 and 37:
BOX 2.6Efforts by the Task Force to
Page 38 and 39:
CHAPTER 3TB case notificationsand t
Page 40 and 41:
BOX 3.1 1Definitions of TB casesDef
Page 42 and 43:
TABLE 3.3 Contribution of public-pr
Page 44 and 45:
BOX 3.4Integrating community-based
Page 46 and 47:
TABLE 3.4 Estimates of the case det
Page 48 and 49:
TABLE 3.5 Treatment success for new
Page 50 and 51:
CHAPTER 4Drug-resistant TBKEY FACTS
Page 52 and 53:
FIGURE 4.2 Percentage of new TB cas
Page 54 and 55:
BOX 4.1Frequencies of resistance to
Page 56 and 57:
FIGURE 4.6 Number of MDR-TB cases e
Page 58 and 59:
FIGURE 4.7Notified cases of MDR-TB
Page 60 and 61:
egimens globally, providing more su
Page 62 and 63:
5.1 Funding for TB care and control
Page 64 and 65:
TABLE 5.2 NTP budgets, available fu
Page 66 and 67:
FIGURE 5.5Trends in domestic and do
Page 68 and 69:
FIGURE 5.6Domestic funding as a per
Page 70 and 71:
FIGURE 5.8Cost per TB patient succe
Page 72 and 73:
FIGURE 5.10 Total cost and unit cos
Page 74 and 75:
● The 14 countries not included i
Page 76 and 77:
on public health by an external Exp
Page 78 and 79:
evised as a result of the introduct
Page 80 and 81:
TABLE 6.2 Incorporation of WHO poli
Page 82 and 83:
FIGURE 6.3The Supranational Referen
Page 84 and 85:
of TB disease by 65%, irrespective
Page 86 and 87:
FIGURE 7.3Percentage of TB patients
Page 88 and 89: BOX 7.1Accelerating progress in pro
Page 90 and 91: TABLE 7.2 Assumptions used to estim
Page 92 and 93: FIGURE 8.1 The development pipeline
Page 94 and 95: sputum specimens and TB isolates fr
Page 96 and 97: cal trial sites and building labora
Page 98: new TB vaccine candidate. A Phase I
Page 102 and 103: This annex explains the methods tha
Page 104 and 105: 2011. On average, 15 data points we
Page 106 and 107: may suffer from biases. These biase
Page 108 and 109: TABLE A1.3Parameter estimates used
Page 110 and 111: 5. Estimates of TB prevalence, 1990
Page 112: the Republic of Moldova, Romania, t
Page 116 and 117: AFGHANISTANPopulation 2011 32 milli
Page 118 and 119: BRAZILPopulation 2011 197 millionHI
Page 120 and 121: CHINAPopulation 2011 1 348 millionH
Page 122 and 123: ETHIOPIAPopulation 2011 85 millionH
Page 124 and 125: INDONESIAPopulation 2011 242 millio
Page 126 and 127: MOZAMBIQUEPopulation 2011 24 millio
Page 128 and 129: NIGERIAPopulation 2011 162 millionH
Page 130 and 131: PHILIPPINESPopulation 2011 95 milli
Page 132 and 133: SOUTH AFRICAPopulation 2011 50 mill
Page 134 and 135: UGANDAPopulation 2011 35 millionHIG
Page 136 and 137: VIET NAMPopulation 2011 89 millionH
Page 138: ANNEX 3Regional profiles
Page 143 and 144: WHO EUROPEAN REGIONPopulation 2011
Page 145 and 146: WHO WESTERN PACIFIC REGIONPopulatio
Page 148 and 149: SUMMARY BY WHO REGIONTable A4.1 Est
Page 150 and 151: MORTALITY (EXCLUDING HIV) PREVALENC
Page 152 and 153: NEW AND RELAPSENOTIFICATION RATE aY
Page 154 and 155: -% OF TB PATIENTS WITHKNOWN HIV STA
Page 156 and 157: AFRICAN REGIONTable A4.1 Estimates
Page 162 and 163: INCIDENCE (INCLUDING HIV) INCIDENCE
Page 164 and 165: NEW AND RELAPSENOTIFICATION RATE aY
Page 166 and 167: NEW AND RELAPSENOTIFICATION RATE a1
Page 168 and 169: TREATMENT SUCCESS (%) a1995-2010YEA
Page 174 and 175: -% OF TB PATIENTS WITHKNOWN HIV STA
Page 176 and 177: YEARTOTALCONFIRMEDCASES OFMDR-TB aE
Page 178 and 179: MALEYEAR 0-14 15-24 25-34 35-44 45-
Page 180 and 181: REGION OF THE AMERICASTable A4.1 Es
Page 186 and 187: INCIDENCE (INCLUDING HIV) INCIDENCE
Page 188 and 189: NEW AND RELAPSENOTIFICATION RATE a1
Page 190 and 191:
NEW AND RELAPSENOTIFICATION RATE a1
Page 192 and 193:
% OF COHORTTREATMENT SUCCESS (%) a1
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
-% OF TB PATIENTS WITHKNOWN HIV STA
Page 200 and 201:
YEARTOTALCONFIRMEDCASES OFMDR-TB aE
Page 202 and 203:
MALEFEMALEYEAR 0-14 15-24 25-34 35-
Page 204 and 205:
EASTERN MEDITERRANEAN REGIONTable A
Page 206 and 207:
MORTALITY (EXCLUDING HIV) PREVALENC
Page 208 and 209:
INCIDENCE (INCLUDING HIV) INCIDENCE
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
EUROPEAN REGIONTable A4.1 Estimates
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
SOUTH-EAST ASIA REGIONTable A4.1 Es
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258:
SMEAR LABS % OF SMEARPER 100K LABS
Page 261 and 262:
Estimates of mortality, prevalence
Page 263 and 264:
YEARPOPULATION(MILLIONS)MORTALITY (
Page 265 and 266:
YEARPOPULATION(MILLIONS)INCIDENCE (
Page 267 and 268:
YEARPOPULATION(MILLIONS)INCIDENCE (
Page 269 and 270:
Page 271 and 272:
TREATMENT SUCCESS (%) a1995-2010YEA
Page 273 and 274:
TREATMENT SUCCESS (%) a1995-2010YEA
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
SMEAR LABS % OF SMEARPER 100K LABS
show all

Global Tuberculosis Report -- 2012.pdf

Create successful ePaper yourself

Delete template?

Save as template?